Eugia Pharma gets USFDA Approval for Amphotericin B Liposome for Injection

Eugia Pharma gets USFDA Approval for Amphotericin B Liposome for Injection

by admin- Friday, November 18th, 2022 04:22:07 PM

Aurobindo Pharma announced that its wholly owned subsidiary business enterprise, Eugia Pharma Specialities Ltd, has acquired a very last approval from the United States Food & Drug Administration (USFDA) for Amphotericin B Liposome for Injection, 50 mg. Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial to be bioequivalent and therapeutically equivalent to the reference indexed drug (RLD), AmBisome Liposome for Injection, 50 mg/vial, of Astellas Pharma US, Inc.. The product is expected to be released via Q4 FY23. The accredited product has an estimated marketplace length of around US$ one hundred forty five million for the twelve months September 2022, consistent with IQVIA.

This is a partnership product from TTY Biopharm Company Limited and might be manufactured at their Taiwan facility and advertised by way of Eugia Pharma.

News Updates